From: Issues on peritoneal metastasis of gastric cancer: an update
Authors reference | Year | Country | Patients | N | IP therapy | Systemic therapy | MST (m) | 1-year OS (%) | R0 resection (%) |
---|---|---|---|---|---|---|---|---|---|
Yamaguchi [51] | 2013 | Japan | GC patients with PM | 35 | PTX | PTX+S1 | 17.6 | 77.1 | 60.0 |
Kitayama [52] | 2014 | Japan | GC patients with PM | 64 | PTX | PTX+S1 | 26.4 | 82.0 | 53.1 |
Badgwell [57] | 2017 | USA | GC patients with PM | 19 | HIPEC MMC and CDDP | 5-Fu+ oxaliplatin | 30.2 | 94.7 | 26.3 |
Yonemura [6] | 2017 | Japan | GC patients with PM | 52 | HIPEC DTX and CDDP | DTX, CDDP and S1 | 19.2 | - | 57.6 |